Outcomes of Valve-In-Valve Transcatheter Aortic Valve Replacement

Structural valve degeneration (SVD) is increasingly seen given the higher rates of bioprosthetic heart valve (BHV) usage for surgical and transcatheter aortic valve replacement (TAVR). Valve-in-valve TAVR (VIV-TAVR) is an attractive alternate for patients who are otherwise at high risk for reoperative surgery. We compared patients undergoing VIV-TAVR and native-valve TAVR through a retrospective analysis of our institutional TVT database from 2013 to 2022. Patients undergoing either a native-valve TAVR or VIV-TAVR were included.

Source: The American Journal of Cardiology - January 15, 2024 Category: Cardiology Authors: Danial Ahmad, Sarah Yousef, Dustin Kliner, James A. Brown, Derek Serna-Gallegos, Catalin Toma, Amber Makani, David West, Yisi Wang, Floyd W. Thoma, Ibrahim Sultan Source Type: research